麒麟集团(08109.HK)发行本金额1,429万元可换股票据抵债
麒麟集团控股(08109.HK)公布,公司与五名认购人订立协议,同意向认购人发行本金总额合共1,429万元之可换股票据,初步换股价为每股新股份0.31元,票据之持有人可按该价格认购新股份。换股价较股份最後交易日联交所收市价每股0.3元溢价约3.33%。换股股份为4,609.7万股,占公司现有已发行股本约10.32%;及经扩大後的公司已发行股本约9.36%。
票据到期日为发行日满第一周年当日,将按每年2%之票息率计息。认购事项将不会产生任何所得款项,认购人同意认购票据,票据将抵销公司根据债项应付之款项。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.